356 related articles for article (PubMed ID: 15543587)
1. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains.
Minor PD; Dunn G; Ramsay ME; Brown D
J Med Virol; 2005 Jan; 75(1):153-60. PubMed ID: 15543587
[TBL] [Abstract][Full Text] [Related]
2. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.
Laassri M; Lottenbach K; Belshe R; Wolff M; Rennels M; Plotkin S; Chumakov K
J Infect Dis; 2005 Dec; 192(12):2092-8. PubMed ID: 16288372
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa.
Pavlov DN; Van Zyl WB; Van Heerden J; Kruger M; Blignaut L; Grabow WO; Ehlers MM
J Appl Microbiol; 2006 Dec; 101(6):1367-79. PubMed ID: 17105568
[TBL] [Abstract][Full Text] [Related]
4. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion.
Abbink F; Buisman AM; Doornbos G; Woldman J; Kimman TG; Conyn-van Spaendonck MA
J Infect Dis; 2005 Mar; 191(6):990-9. PubMed ID: 15717277
[TBL] [Abstract][Full Text] [Related]
5. Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children.
Samoilovich E; Roivainen M; Titov LP; Hovi T
J Med Virol; 2003 Oct; 71(2):274-80. PubMed ID: 12938203
[TBL] [Abstract][Full Text] [Related]
6. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines.
Ramsay ME; Begg NT; Gandhi J; Brown D
Pediatr Infect Dis J; 1994 Dec; 13(12):1117-21. PubMed ID: 7892081
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary.
Kapusinszky B; Molnár Z; Szomor KN; Berencsi G
FEMS Immunol Med Microbiol; 2010 Mar; 58(2):211-7. PubMed ID: 19863665
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
[TBL] [Abstract][Full Text] [Related]
9. Live-attenuated strains of improved genetic stability.
Macadam AJ; Ferguson G; Stone DM; Meredith J; Almond JW; Minor PD
Dev Biol (Basel); 2001; 105():179-87. PubMed ID: 11763326
[TBL] [Abstract][Full Text] [Related]
10. [Isolates of poliovirus vaccine and immune response to different doses of oral polio vaccine].
Más Lago P; Díaz J; Díaz Gonzalez M; Goyenechea Hernández A; Barrio Olivera J; Fonseca Quintana M; Morier Díaz L; Sarmiento Pérez L; Palomera Puente R
Rev Cubana Med Trop; 2005; 57(2):111-9. PubMed ID: 17966580
[TBL] [Abstract][Full Text] [Related]
11. Booster effect of oral poliovaccine. Trials in persons previously immunized with inactivated vaccine.
McCollough RH; Glezen WP; Lamb GA; Chin TD
Am J Dis Child; 1969 Feb; 117(2):161-8. PubMed ID: 4303394
[No Abstract] [Full Text] [Related]
12. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
Laassri M; Lottenbach K; Belshe R; Rennels M; Plotkin S; Chumakov K
J Infect Dis; 2006 May; 193(10):1344-9. PubMed ID: 16619180
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on Vero cells or on primary monkey kidney cells.
Mallet L; Pelloquin F; Brigaud M; Caudrelier P; Bandet R; Xueref C; Fuchs F; Gibelin N; Goldman C; Moulin JC; de Fraipont F; Montagnon B; Peyron L; Aymard M
J Med Virol; 1997 May; 52(1):50-60. PubMed ID: 9131458
[TBL] [Abstract][Full Text] [Related]
14. [The spread of the wild Poliovirus in the rural environment, the case of the Adzopé health district, Côte d'Ivoire].
Akoua-Koffi CG; Nekouressi G; Tieoulou L; Guillot S; Faye-Kette H; Ehouman A
Bull Soc Pathol Exot; 2004 May; 97(2):87-90. PubMed ID: 15255346
[TBL] [Abstract][Full Text] [Related]
15. Shedding of sabin poliovirus Type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine.
Martinez CV; Old MO; Kwock DK; Khan SS; Garcia JJ; Chan CS; Webster R; Falkovitz-Halpern MS; Maldonado YA
J Infect Dis; 2004 Jul; 190(2):409-16. PubMed ID: 15216480
[TBL] [Abstract][Full Text] [Related]
16. Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand.
Huang QS; Greening G; Baker MG; Grimwood K; Hewitt J; Hulston D; van Duin L; Fitzsimons A; Garrett N; Graham D; Lennon D; Shimizu H; Miyamura T; Pallansch MA
Lancet; 2005 Jul 30-Aug 5; 366(9483):394-6. PubMed ID: 16054940
[TBL] [Abstract][Full Text] [Related]
17. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel.
Swartz TA; Green MS; Handscher R; Sofer D; Cohen-Dar M; Shohat T; Habib S; Barak E; Dror Z; Somekh E; Peled-Leviathan T; Yulzari R; Libling A; Mendelson E; Shulman LM
Vaccine; 2008 Feb; 26(8):1083-90. PubMed ID: 18241962
[TBL] [Abstract][Full Text] [Related]
18. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
[TBL] [Abstract][Full Text] [Related]
19. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
20. Long-term excretion of vaccine-derived poliovirus by a healthy child.
Martín J; Odoom K; Tuite G; Dunn G; Hopewell N; Cooper G; Fitzharris C; Butler K; Hall WW; Minor PD
J Virol; 2004 Dec; 78(24):13839-47. PubMed ID: 15564492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
